<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289938</url>
  </required_header>
  <id_info>
    <org_study_id>IKP231</org_study_id>
    <secondary_id>2008-003778-16</secondary_id>
    <nct_id>NCT01289938</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine</brief_title>
  <acronym>MalD</acronym>
  <official_title>Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Schwab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and
      Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to
      polymorphisms of CYP2D6
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are
    completed (EM, IM and PM).
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve of metoclopramide (MCP)</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Pharmacokinetic of MCP at following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve of diphenhydramine(DPH)</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Pharmacokinetics of DPH at following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of metoclopramide</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Cmax of metoclopramide at following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of metoclopramide</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Tmax of metoclopramide at following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of diphenhydramine</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Cmax of diphenhydramine at the following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of diphenhydramine</measure>
    <time_frame>0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours</time_frame>
    <description>Tmax of diphenhydramine at the following time points:
0,5, 1, 1,5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72 hours after drug application</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Drug Metabolism, Poor, CYP2D6-RELATED</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diphenhydramine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramine 50 mg oral once</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <other_name>DPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>10 mg i.v. metoclopramide once</description>
    <arm_group_label>Metoclopramide</arm_group_label>
    <other_name>MCP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 20 - 27kg/m2

          -  Caucasians

          -  Healthy volunteers

        Exclusion Criteria:

          -  Pregnancy/lactation period

          -  Drug allergy

          -  Acute and chronic diseases

          -  Taking medication

          -  Abuse of drugs, alcohol etc.

          -  Smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schwab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abteilung Klinische Pharmakologie, UKT Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. Epub 2006 Oct 4. Review.</citation>
    <PMID>17113714</PMID>
  </reference>
  <reference>
    <citation>Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187-93.</citation>
    <PMID>18024866</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Matthias Schwab</investigator_full_name>
    <investigator_title>Prof. M.D.</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacogenetic</keyword>
  <keyword>Metoclopramide</keyword>
  <keyword>Diphenhydramine</keyword>
  <keyword>CYP2D6 polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

